(Q54373981)

English

Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.

scientific article published in March 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

1 reference

based on heuristic

inferred from title

author name string

Ning Li

1

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Wei Ou

2

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Xiong Ye

3

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Hai-Bo Sun

4

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Liang Zhang

5

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Qin Fang

6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Song-Liang Zhang

7

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Bao-Xiao Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Si-Yu Wang

9

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

publication date

1 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Annals of Surgical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

21

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

2091-2096

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Revisions in the International System for Staging Lung Cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Association between hormone receptor expression and epidermal growth factor receptor mutation in patients operated on for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-014-3586-9

21 January 2018

Identifiers

10.1245/S10434-014-3586-9

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Dimensions Publication ID

0 references

release_bew7vkzg25aetkjibguns2nxwa

1 reference

https://api.fatcat.wiki/v0/release/bew7vkzg25aetkjibguns2nxwa

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/24585406

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54373981&oldid=2212443859"